According to a recent LinkedIn post from SurGenTec, the company is highlighting new peer‑reviewed data on its OsteoFlo HydroFiber synthetic bone graft published in Global Spine Journal. The post describes a large independently conducted study using the Boden Spine Model that evaluated posterolateral spinal fusion with multiple imaging and assessment modalities over time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that HydroFiber demonstrated fusion outcomes considered equivalent to autograft, which is widely viewed as the clinical gold standard. It further notes that adding autograft to HydroFiber reportedly did not improve outcomes versus HydroFiber alone, positioning the product as a potential standalone option in relevant spinal fusion procedures.
As described in the post, HydroFiber is currently FDA‑cleared as equivalent to autograft and indicated for use across cervical, thoracic, and lumbar applications, including disc spaces, interbody cages, and lateral gutters, as well as for certain trauma and bone void filling indications. For investors, peer‑reviewed validation and broad indications may support adoption in spine surgery, potentially strengthening SurGenTec’s competitive position in the synthetic bone graft market.
If the study’s findings gain traction among surgeons and payors, the data could help drive increased utilization versus traditional autograft and other synthetic grafts. That dynamic could expand SurGenTec’s revenue opportunity in spinal fusion and related procedures, though market uptake will ultimately depend on real‑world outcomes, pricing, reimbursement, and competitive responses from larger orthopedic device manufacturers.